



NEWS RELEASE

# Mast Therapeutics To Present At Cowen And Company 36th Annual Health Care Conference On March 7th

2016-03-01

SAN DIEGO, March 1, 2016 /PRNewswire/ -- **Mast Therapeutics, Inc.** (NYSE MKT: MSTX), a biopharmaceutical company developing novel clinical-stage therapies for sickle cell disease and heart failure today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Cowen and Company 36<sup>th</sup> Annual Health Care Conference on Monday, March 7, 2016 at 2:00 p.m. Eastern time in Salon H at the Boston Marriott Copley Place hotel in Boston.

Interested parties can access a live audio webcast on the Mast Therapeutics web site at [www.masttherapeutics.com](http://www.masttherapeutics.com). An archived presentation will be available on the web site for 30 days.

## About Mast Therapeutics

Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is developing two clinical-stage investigational new drugs for serious or life-threatening diseases and conditions. Vepoloxamer, the Company's lead product candidate, is in Phase 3 clinical development for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in Phase 2 clinical development for the treatment of patients with heart failure. Enrollment in the Company's 388-patient Phase 3 study of vepoloxamer in patients with sickle cell disease, known as the EPIC study, was completed in February 2016. Enrollment in the Company's Phase 2 study of vepoloxamer in patients with chronic heart failure is ongoing. AIR001, the Company's second product candidate, is in Phase 2 clinical development for the treatment of patients with heart failure with preserved ejection fraction (HFpEF). Enrollment in a Phase 2a study of AIR001 in patients with HFpEF is ongoing and AIR001 was recently selected by the Heart Failure Clinical Research Network for evaluation in a 100-patient,



multicenter, randomized, double-blind, placebo-controlled, Phase 2 study in patients with HFpEF. More information can be found on the Company's web site at [www.masttherapeutics.com](http://www.masttherapeutics.com). (Twitter: @MastThera)

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Logo - <http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/mast-therapeutics-to-present-at-cowen-and-company-36th-annual-health-care-conference-on-march-7th-300228375.html>

SOURCE Mast Therapeutics, Inc.

Mast Therapeutics, Ioana C. Hone (ir@mastthera.com), 858-552-0866 Ext. 303